DelveInsight’s, “Thyroid Cancer Pipeline Insight 2023” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including Thyroid Cancer clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Thyroid Cancer Emerging drugs, the Thyroid Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Thyroid Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Thyroid Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Thyroid Cancer clinical trials studies, Thyroid Cancer NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Thyroid Cancer Pipeline Report
- DelveInsight’s Thyroid Cancer Pipeline analysis depicts a robust space with 40+ active players working to develop 40+ pipeline treatment therapies.
- The leading Thyroid Cancer Companies includes Shanghai Henlius Biotech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD, Bristol-Myers Squibb, Takeda Oncology, Merck Sharp & Dohme Corp., Genentech, Inc., VBL Therapeutics, Eli Lilly and Company, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Purple Biotech, Boston Pharmaceuticals, Xynomic Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Iovance Biotherapeutics, Inc., Hoffmann-La Roche, Hutchison Medipharma Limited, Theratechnologies, TransThera Sciences (Nanjing), Inc., Novartis Oncology, SOTIO Biotech AG, Ono Pharmaceutical, Debiopharm, Tmunity Therapeutics, Codiak BioSciences, Oncoceutics, GlobeImmune, C4 Therapeutics, Innovative Cellular Therapeutics, Applied Pharmaceutical, and others
- Promising Thyroid Cancer pipeline therapies include HLX208, AIC100, HX008, Nivolumab, Ipilimumab, MLN0128, Pembrolizumab, Vemurafenib, VB-111, LOXO-260, Anlotinib hydrochloride, HA121-28, CM-24, BOS172738, XP-102, TPX-0046, LN 145, Alectinib, Surufatinib, TH1902, TT-00420, Spartalizumab, SO-C101, LY3410738, Binimetinib, DEBIO 1124, CDK-002, ONC201, GI 6207, APS03118, exoASO STAT6, and others.
- The Thyroid Cancer companies and academics are working to assess challenges and seek opportunities that could influence Thyroid Cancer R&D. The Thyroid Cancer pipeline therapies under development are focused on novel approaches to treat/improve Thyroid Cancer.
Request a sample and discover the recent breakthroughs happening in the Thyroid Cancer Pipeline landscape @ Thyroid Cancer Pipeline Outlook Report
Thyroid Cancer Overview
Thyroid cancer starts in the cells that make up your thyroid gland. The thyroid gland makes hormones that help control many processes in your body. Thyroid cancer is relatively common enough so that all of us will know somebody with thyroid cancer. There are more than 50,000 new cases of thyroid cancer each year in the United States. Women are more likely to develop thyroid cancer at a ratio of three to one. Thyroid cancer can occur in any age group, although it is most common after age 30 and its aggressiveness increases significantly in patients above 55 years of age.
Recent Developmental Activities in the Thyroid Cancer Pipeline Report
- In April 2022, Molecular Targeting Technologies Inc. (MTTI) and ITM Isotope Technologies Munich SE (ITM) announced the signing of a global clinical supply agreement that provides MTTI with ITM’s medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu / EndolucinBeta®) for the preclinical and clinical development as well as potential commercial production of MTTI’s radiopharmaceutical candidate n.c.a. 177Lu-EBTATE to treat a range of cancers. N.c.a. 177Lu-EBTATE is currently in clinical development for the treatment of neuroendocrine tumors, a special form of thyroid cancer (Hürthle cell), and a rare type of head and neck cancer (nasopharyngeal cancer).
- In April 2022, Purple Biotech Ltd., announced favorable safety and efficacy data supporting the advancement of CM24, a first-in-class clinical-stage monoclonal antibody with the potential to treat multiple solid tumor cancers.
- In January 2022, Applied Pharmaceutical Science, Inc. announced the Investigational New Drug (IND) application for APS03118, a next-generation selective RET inhibitor, which has been approved by the U.S. Food and Drug Administration (FDA). The clinical application is also in the process of being submitted to the National Medical Products Administration (NMPA) in China, and a global multi-center clinical trial is in the pipeline for initiation in the second quarter of 2022 in the U.S., China, and Australia, etc.
- In May 2021, AffyImmune Therapeutics announced that the US Food and Drug Administration (FDA) granted Fast Track designation to its lead compound, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.
For further information, refer to the detailed Thyroid Cancer Drugs Launch, Thyroid Cancer Developmental Activities, and Thyroid Cancer News, click here for Thyroid Cancer Ongoing Clinical Trial Analysis
Thyroid Cancer Emerging Drugs Profile
- Donafenib: Suzhou Zelgen Biopharmaceuticals
Donafenib, an orally administered multikinase inhibitor, is being developed by Suzhou Zelgen Biopharmaceuticals for the treatment of Late stage cancers. The product targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.
- Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
Anlotinib is an orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.
- Nivolumab: Bristol-Myers Squibb
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Currently, it is in phase 2 of development stage for the treatment of thyroid cancer.
- RX208: Suzhou NeuPharma
RX108 is a novel small-molecule inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase). Na+/K+-ATPase is an ion carrier protein and controls transportation of Na+ and K+ across the cell membrane. Studies have shown that Na+/K+-ATPase serves as a scaffold for the assembly of multiple-protein signaling complex and plays an important role in the regulation of cell growth, motility, and proliferation beyond that of ion transport. Expression of Na+/K+-ATPase is elevated in various tumors. Inhibition of Na+/K+-ATPase in cancer cells triggers a series of downstream signaling activities that lead to cell-cycle arrest, apoptosis and autophagic cell death. Targeting Na+/K+-ATPase offers a potential new approach for the development of novel anti-cancer therapies.
- AIC100: AffyImmune Therapeutics
AffyImmune’s lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100’s CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity.Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. AffyImmune is currently enrolling patients in our Phase I trial for ARTC.
Thyroid Cancer Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the therapies for Thyroid Cancer. The companies which have their Thyroid Cancer drug candidates in the most advanced stage, i.e. phase III include, Suzhou Zelgen Biopharmaceuticals
Find out more about the Thyroid Cancer Pipeline Segmentation, Therapeutics Assessment, and Thyroid Cancer Emerging Drugs @ Thyroid Cancer Treatment Landscape
Scope of the Thyroid Cancer Pipeline Report
- Coverage- Global
- Thyroid Cancer Companies- Shanghai Henlius Biotech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD, Bristol-Myers Squibb, Takeda Oncology, Merck Sharp & Dohme Corp., Genentech, Inc., VBL Therapeutics, Eli Lilly and Company, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Purple Biotech, Boston Pharmaceuticals, Xynomic Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Iovance Biotherapeutics, Inc., Hoffmann-La Roche, Hutchison Medipharma Limited, Theratechnologies, TransThera Sciences (Nanjing), Inc., Novartis Oncology, SOTIO Biotech AG, Ono Pharmaceutical, Debiopharm, Tmunity Therapeutics, Codiak BioSciences, Oncoceutics, GlobeImmune, C4 Therapeutics, Innovative Cellular Therapeutics, Applied Pharmaceutical, and others
- Thyroid Cancer pipeline therapies- HLX208, AIC100, HX008, Nivolumab, Ipilimumab, MLN0128, Pembrolizumab, Vemurafenib, VB-111, LOXO-260, Anlotinib hydrochloride, HA121-28, CM-24, BOS172738, XP-102, TPX-0046, LN 145, Alectinib, Surufatinib, TH1902, TT-00420, Spartalizumab, SO-C101, LY3410738, Binimetinib, DEBIO 1124, CDK-002, ONC201, GI 6207, APS03118, exoASO STAT6, and others.
- Thyroid Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Thyroid Cancer Pipeline Companies and Therapies, click here @ Thyroid Cancer Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Thyroid Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Thyroid Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Donafenib: Suzhou Zelgen Biopharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Nivolumab: Bristol-Myers Squibb
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AIC100: Affyimmune Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Thyroid Cancer Key Companies
- Thyroid Cancer Key Products
- Thyroid Cancer- Unmet Needs
- Thyroid Cancer- Market Drivers and Barriers
- Thyroid Cancer- Future Perspectives and Conclusion
- Thyroid Cancer Analyst Views
- Thyroid Cancer Key Companies
- Appendix
Got Queries? Find out the related information on Thyroid Cancer Mergers and acquisitions, Thyroid Cancer Licensing Activities @ Thyroid Cancer Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/